This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Harmony Biosciences Holdings, Inc. (HRMY) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.
J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits
by Zacks Equity Research
A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.
How Much Upside is Left in 2seventy bio, Inc. (TSVT)? Wall Street Analysts Think 127.63%
by Zacks Equity Research
The consensus price target hints at a 127.6% upside potential for 2seventy bio, Inc. (TSVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
bluebird (BLUE) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.
bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale
by Zacks Equity Research
bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.
bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.
2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Does 2seventy bio, Inc. (TSVT) Have the Potential to Rally 97% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 96.9% in 2seventy bio, Inc. (TSVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
Bristol Myers (BMY) Posts Data From Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.
bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
by Zacks Equity Research
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review
by Zacks Equity Research
bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.
bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss
by Zacks Equity Research
bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.